RDRI Begins First Clinical Trial


The Renal Disease Research Institute (RDRI) is a new research entity affiliated with Dallas Nephrology Associates. There is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee. Currently, there are several potential clinical research trials in the pipeline.

RDRI’s first active clinical trial is a device trial spearheaded by Dr. Neghae Mawla. Dr. Mawla is currently recruiting subjects requiring an arteriovenous fistula placement. The device is an investigation product designed to create an AV fistula percutaneously using only local anesthesia and no open surgical method. Clinicians may reach out to Dr. Mawla to discuss inclusion and exclusion criteria.

But, many wonder – why would a patient participate in research? The literature shows several reasons. First, patients realize that participating in research gives them access to investigational therapies to which they may not otherwise have access. Also, added physicians and staff members dedicated to a patient’s investigational treatment gives the patient a perceived higher quality of care. Many patients state that they feel a sense of accomplishment by simply helping the scientific community.

Clinicians understand that the practice of medicine is driven by evidence. Participation in clinical research trials develops this evidence, but there are many additional reasons why clinicians choose to take part in research. Participation in clinical research studies allows clinicians to remain on the cutting edge of new science, as well as provide novel treatments to their patients. Joining a clinical research trial can enhance the prestige of a clinician’s practice. Additionally, there is an increase in academic collaboration amongst clinical investigators. Clinicians strive to positively affect the way their patient is cared for, and can impact the science of medicine while doing so.

For more information on RDRI and its active research trials, please visit renaldiseaseresearch.com.